Index

abnormal sensations 81
absence seizures 21–2, 247
absence seizures with special features 22
absence status epilepticus 347
adrenocorticotropic hormone (ACTH) 102
adverse effects 179
adverse effects of AEDs 175–8
adrenocorticotropic hormone (ACTH) 179
at-risk profiles and monitoring 189–91
carbamazepine 179
clobazam 179–80
ehosuximide 180
ezogabine 180
felbamate 180–1
gabapentin 181
lacosamide 181–2
lamotrigine 182
levetiracetam 182
oxcarbazepine 182–4
phenobarbital 184
phenytoin 184–5
pregabalin 185
rufinamide 185–6
tiagabine 186
topiramate 186
valproate 187–8
vigabatrin 188–9
zonisamide 189

agenesis of corpus callosum (ACC) neuroimaging 117–18
age-related differences 4–5
EEG 102–4
specific age-related epilepsy syndromes 25–34
alternating hemiplegia of childhood (AHC) 136–7
Angelman syndrome 64
angiography 115
anterior frontopolar epilepsy 305
antiepileptic drugs (AEDs) 37–9
adverse effects 175–8
adrenocorticotropic hormone (ACTH) 179
at-risk profiles and monitoring 189–91
carbamazepine 179
clobazam 179–80
ethosuximide 180
ezogabine 180
felbamate 180–1
gabapentin 181
lacosamide 181–2
lamotrigine 182
levetiracetam 182
oxcarbazepine 182–4
phenobarbital 184
phenytoin 184–5
pregabalin 185
INDEX

antiepileptic drugs (AEDs) (Continued)
  rufinamide 185–6
  tiagabine 186
  topiramate 186
  valproate 187–8
  vigabatrin 188–9
  zonisamide 189
benefits 45
initiation 45–8
key questions when initiating AED therapy
  39
pharmacogenomics 155–6
  metabolizing pathways 156–7
pharmacokinetics 145
  absorption 146–7
  distribution 147–8
  elimination 150
  metabolism 148–50
  pharmacokinetic parameters 150–3
  therapeutic drug monitoring (TDM) 153–5
risks 44–5
therapeutic efficacy 159–60, 172
  BECTs 169
  childhood and juvenile absence epilepsy
    170
  childhood absence epilepsy
    170
  comorbidities in children 171–2
  Dravet syndrome 169
  efficacy-based treatment guidelines
    160–4
  epileptic encephalopathy with continuous
    spike-and-wave during sleep
    (ESES/CSWS) 169
  febrile seizures 168
  infantile spasms 168
  juvenile myoclonic epilepsy (JME) 170
  Landau–Kleffner syndrome 169
  Lennox–Gastaut syndrome 168
  neonatal seizures 164–8
  partial-onset seizures 170–1
  specific pediatric epilepsy syndromes
    164–71
withdrawal 51
  benefits 55
  disadvantages 54
  procedure 55
  risk of seizure recurrence 51–4
  special circumstances 55–6
  summary 56–7
anxiety 10–11
  case studies
    dizziness 11
  prevalence with epilepsy 9

Atkins diet, modified 226
efficacy 227
atropine 131
attention-deficit/hyperactivity disorder
  (ADHD) 9
  case studies
    disruptive behavior 10
    inattentiveness 9–10
  Conners Parent Rating Scale 83
  prevalence with epilepsy 9, 83
  atypical absence seizures 21
  aura continua 347–8
  autosomal dominant lateral temporal lobe
    epilepsy (ADLTE) 62–3
  genes identified 61
  autosomal dominant nocturnal frontal lobe
    epilepsy (ADNFLE) 30, 62
  genes identified 61
  ballet posture 20
  benign childhood epilepsy with centrotemporal
    spikes (BECTs) 30, 287–8
  AEDs
    therapeutic efficacy 169
    clinical features 288
    demographics 288
    diagnostic workup 289
    EEG 96
    etiology 288–9
    treatment 289
  benign familial infantile epilepsy/seizures
    (BFIE/BFIS) 27, 60
  genes identified 61
  benign familial neonatal epilepsy/seizures
    (BFNE/BFNS) 25, 60
  genes identified 61
  benign familial neonatal-infantile epilepsy/
    seizures (BFNE/BNFIS) 60
  genes identified 61
  benign infantile epilepsy 27
  benign infantile seizures 286
  clinical features 286
  demographics 286
  diagnostic workup 287
  etiology 287
  treatment 287
  benign myoclonic epilepsy (BME)
    EEG 99–102
  benign paroxysmal positional vertigo of
    childhood (BPVC) 133–4
  benign rolandic epilepsy with centrotemporal
    spikes (BECTs) 78
INDEX

benign sleep myoclonus of infancy 133
bilaterally independent periodic lateralizing
epileptiform discharges (BiPLEDs) 354
bioavailability 146
bioequivalence 146
biotinidase deficiency 65
Bourneville disease 120–3
breath-holding spells (BHS) 130–1
carbamazepine
   adverse effects 177, 179
   drug interactions 154
   initiating therapy 46
   metabolism and excretion 148–50
   pharmacokinetic parameters 151
case studies
   disinterest in activities 12
   disruptive behavior 10
   dizziness 11
   inattentiveness 9–10
cavernomas 126–7
cerebral angiography 115
Child Depression Inventory 83
childhood absence epilepsy (CAE) 32–3, 250
   clinical manifestations 251
   EEG 99–102, 251
   epidemiology 250
   genes identified 61
   genetics 250–1
   natural history 251
   treatment 251–2
childhood and juvenile absence epilepsy
   AEDs
      therapeutic efficacy 170
childhood occipital epilepsy 289
   clinical features 290–1
demographics 290
diagnostic workup 291–2
etiology 291
   treatment 292
chromosomal abnormalities 63
Angelman syndrome 64
Miller–Diecker syndrome (MDS) 65
Rett syndrome 64
ring chromosome-20 65
Wolf–Hirschhorn syndrome 63–4
cinglet gyrus epilepsy 304–5
classification of epilepsy 5–6, 17
epilepsy syndromes 23
electroclinical syndromes 24
organization 23–5
   specific age-related syndromes 25–34
focal epileptic seizures 22
future directions 34
generalized epileptic seizures 19
   absence seizures 21–2
   clonic seizures 20
   myoclonic seizures 20–2
   tonic seizures 20
   tonic–clonic seizures 20
purpose and goals 17–18
   seizures 18–19
   systems 18
clobazam
   adverse effects 179–80
   drug interactions 154
   metabolism and excretion 149
   pharmacokinetic parameters 151
   clonic seizures 20
complex partial status epilepticus 347
computerized tomography (CT) 78, 85
imaging considerations 107–8
congenital malformations
   neuroimaging 117–19
   agenesis of corpus callosum (ACC) 117–18
   focal cortical dysplasia (FCD) 117
   hamartomas of hypothalamus 119
   hemimegaloencephaly 117
   phakomatoses 120–4
   polymicrogyria 118–19
   schizencephaly 119
   Sturge-Weber syndrome 123–4
   tuberous sclerosis complex (TSC) 120–3
Conners Parent Rating Scale for ADHD 83
corpus callostomy 213–14
cortical deformations 66–7
cryptogenic epilepsy 59
cryptogenic partial epilepsies 296
   etiology 296
   seizure phenomena 297
cryptogenic seizure etiology 40
definitions
   epilepsies 23
   epilepsy syndrome 23
   focal epileptic seizures 19
generalized epileptic seizures 19
   ictal motor events 20
   clonic seizures 20
   tonic seizures 20
   tonic–clonic seizures 20
definitions (Continued)
  incidence 4
  prevalence 4
  seizure etiology 40
  deoxyhemoglobin 114
  depression 11
  case studies
    disinterest in activities 12
    prevalence with epilepsy 9
  dietary therapy 219–20
  candidate selection 232–4
  complications 236–9
    adverse effects of ketogenic diet 238
  efficacy 221–8
    Atkins diet, modified 227
    ketogenic diet 222–3, 224
  history 220
  initiation and maintenance 234
  hospitalization 234–6
  pre-hospital evaluation 234
  mechanism of action 228
  clinical studies 231
  experimental studies 231–2
  ketogenesis 228–31
  recent experience 239
  diffusion tensor imaging (DTI) 112
  diffusion weighted imaging (DWI) 108–9
  Doose syndrome 258, 277–8
  dorsolateral frontal lobe epilepsy 304
  Dravet syndrome 28, 48, 62, 275
  AEDs
    therapeutic efficacy 169
    course and outlook 277
    differential diagnosis 275–7
  EEG 104–5
  etiology 275
  genes identified 61
  treatment 277
  drug reaction with eosinophilia and systemic
    symptoms (DRESS syndrome) 178
  dysembryoplastic neuroepithelial tumor
    (DNET) 125–6
  early infantile epileptic encephalopathy (EIEE) 269
  early myoclonic encephalopathy (EME) 25, 102–4, 268–70
  electrical status epilepticus of slow-wave sleep
    (ESES/CSWS) 32
  electroencephalography (EEG) 77, 84–5, 105
    applicability 92
    febrile seizures 92–3
    non-febrile seizures 93
  childhood absence epilepsy (CAE) 251
  diagnosis in children 90–1
    neonatal 94–6
  disease-related epilepsy syndromes 104–5
  epilepsy with generalised tonic–clonic
    seizures (IGE-GTCs) 257
  epilepsy with myoclonic absence 258
  eyelid myoclonia with absences (EMA) 261
  febrile seizures plus (FS+) 260
  findings in epilepsy and epilepsy syndromes
    93–4
  focal epilepsy 96
    idiopathic 96–7
    symptomatic 98–9
  generalized epilepsy
    age-related syndromes 102–4
    idiopathic 99–102
    symptomatic 102
  intracranial (ICEEG) 208–9
  Jeavons syndrome 261
  juvenile absence epilepsy (JAE) 253
  juvenile myoclonic epilepsy (JME) 254
  methods to increase yield 91–2
  myoclonic epilepsy in infancy 250
  status epilepticus in childhood 352
  bilaterally independent periodic
    lateralizing epileptiform discharges
    (BiPLEDs) 354
  generalised periodic epileptiform
    discharges (GPEds) 354–5
  periodic lateralizing epileptiform
    discharges (PLEDs) 352–3
  stimulus-induced rhythmic, periodic, or
    ictal discharges (SIRPIDs) 355
  triphasic waves (TWs) 355–6
  technical aspects 91
  video (VEEG)
    defining epileptogenic focus 205–6
  epidemiology 3–4, 12
  classification 5–6
  etiology 6
  febrile seizures 6
  gender and age 4–5
  incidence and prevalence 4
  international studies 5
  epilepsy partialis continua 347
<table>
<thead>
<tr>
<th>Condition</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epilepsy of infancy with migrating focal seizures</td>
<td>26</td>
</tr>
<tr>
<td>Epilepsy syndromes</td>
<td>23</td>
</tr>
<tr>
<td>EEG</td>
<td>93–4</td>
</tr>
<tr>
<td>Organization and classification</td>
<td>23–5</td>
</tr>
<tr>
<td>Electroclinical syndromes</td>
<td>24</td>
</tr>
<tr>
<td>Genetic epilepsy syndromes</td>
<td>23</td>
</tr>
<tr>
<td>Structural–metabolic epilepsy syndromes</td>
<td>23</td>
</tr>
<tr>
<td>Unknown cause</td>
<td>23</td>
</tr>
<tr>
<td>Prognosis</td>
<td>53</td>
</tr>
<tr>
<td>Specific age-related syndromes</td>
<td></td>
</tr>
<tr>
<td>Autosomal dominant nocturnal frontal lobe epilepsy</td>
<td>30</td>
</tr>
<tr>
<td>Benign childhood epilepsy with centrotal temporal spikes (BECTs)</td>
<td>30</td>
</tr>
<tr>
<td>Benign familial infantile epilepsy</td>
<td>27</td>
</tr>
<tr>
<td>Benign familial neonatal epilepsy</td>
<td>25</td>
</tr>
<tr>
<td>Benign infantile epilepsy</td>
<td>27</td>
</tr>
<tr>
<td>Childhood absence epilepsy (CAE)</td>
<td>32–3</td>
</tr>
<tr>
<td>Dravet syndrome</td>
<td>28</td>
</tr>
<tr>
<td>Early myoclonic encephalopathy (EME)</td>
<td>25</td>
</tr>
<tr>
<td>Epilepsy of infancy with migrating focal seizures</td>
<td>26</td>
</tr>
<tr>
<td>Epilepsy with myoclonic absences</td>
<td>31</td>
</tr>
<tr>
<td>Epilepsy with myoclonic–atonic seizures</td>
<td>29, 258</td>
</tr>
<tr>
<td>Epileptic encephalopathy with continuous spike-and-wave during sleep</td>
<td>32, 279–80</td>
</tr>
<tr>
<td>(ESES/CSWS)</td>
<td></td>
</tr>
<tr>
<td>Febrile seizures plus (FS+)</td>
<td>28–9</td>
</tr>
<tr>
<td>Juvenile absence epilepsy (JAE)</td>
<td>33</td>
</tr>
<tr>
<td>Juvenile myoclonic epilepsy (JME)</td>
<td>33</td>
</tr>
<tr>
<td>Landau–Kleffner syndrome</td>
<td>32</td>
</tr>
<tr>
<td>Late onset childhood occipital epilepsy (Gastaut type)</td>
<td>30–1</td>
</tr>
<tr>
<td>Lennox–Gastaut syndrome (LGS)</td>
<td>31</td>
</tr>
<tr>
<td>Myoclonic encephalopathy in non-progressive disorders</td>
<td>28</td>
</tr>
<tr>
<td>Myoclonic epilepsy in infancy (MEI)</td>
<td>27</td>
</tr>
<tr>
<td>Ohtahara syndrome</td>
<td>25–6</td>
</tr>
<tr>
<td>Panayiotopolous syndrome</td>
<td>29</td>
</tr>
<tr>
<td>Progressive myoclonus epilepsies (PME)</td>
<td>33–4</td>
</tr>
<tr>
<td>West syndrome</td>
<td>26–7</td>
</tr>
<tr>
<td>Epilepsy with generalised tonic–clonic seizures (IGE-GTCs)</td>
<td>256</td>
</tr>
<tr>
<td>Clinical manifestations</td>
<td>257</td>
</tr>
<tr>
<td>EEG</td>
<td>257</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>257</td>
</tr>
<tr>
<td>Genetics</td>
<td>257</td>
</tr>
<tr>
<td>Natural history</td>
<td>257</td>
</tr>
<tr>
<td>Treatment</td>
<td>257</td>
</tr>
<tr>
<td>Epilepsy with grand mal on awakening (EGMA)</td>
<td></td>
</tr>
<tr>
<td>EEG</td>
<td>99–102</td>
</tr>
<tr>
<td>Epilepsy with myoclonic absence</td>
<td>257</td>
</tr>
<tr>
<td>Clinical manifestations</td>
<td>258</td>
</tr>
<tr>
<td>EEG</td>
<td>258</td>
</tr>
<tr>
<td>Epidemiology</td>
<td>258</td>
</tr>
<tr>
<td>Genetics</td>
<td>258</td>
</tr>
<tr>
<td>Natural history</td>
<td>258</td>
</tr>
<tr>
<td>Treatment</td>
<td>258</td>
</tr>
<tr>
<td>Epilepsy with myoclonic absences</td>
<td>31</td>
</tr>
<tr>
<td>Epilepsy with myoclonic–atonic seizures</td>
<td>29, 258</td>
</tr>
<tr>
<td>Epileptic encephalopathy with continuous spike-and-wave during sleep</td>
<td>32, 279–80</td>
</tr>
<tr>
<td>(ESES/CSWS)</td>
<td></td>
</tr>
<tr>
<td>AEDs</td>
<td></td>
</tr>
<tr>
<td>Therapeutic efficacy</td>
<td>169</td>
</tr>
<tr>
<td>EEG</td>
<td>98–9</td>
</tr>
<tr>
<td>Prognosis</td>
<td>280</td>
</tr>
<tr>
<td>Treatment</td>
<td>280</td>
</tr>
<tr>
<td>Ethosuximide</td>
<td></td>
</tr>
<tr>
<td>Adverse effects</td>
<td>177, 180</td>
</tr>
<tr>
<td>Drug interactions</td>
<td>154</td>
</tr>
<tr>
<td>Initiating therapy</td>
<td>46</td>
</tr>
<tr>
<td>Metabolism and excretion</td>
<td>149</td>
</tr>
<tr>
<td>Pharmacokinetic parameters</td>
<td>151</td>
</tr>
<tr>
<td>Etiology of epilepsy</td>
<td>6</td>
</tr>
<tr>
<td>Evaluation of children</td>
<td>75–6</td>
</tr>
<tr>
<td>Additional neurodiagnostic evaluation</td>
<td>84</td>
</tr>
<tr>
<td>EEG</td>
<td>84–5</td>
</tr>
<tr>
<td>Neuroimaging</td>
<td>85</td>
</tr>
<tr>
<td>Emergent diagnosis and management</td>
<td>76–9</td>
</tr>
<tr>
<td>Subsequent evaluation</td>
<td></td>
</tr>
<tr>
<td>Comorbidities</td>
<td>82–3</td>
</tr>
<tr>
<td>History</td>
<td>79–82</td>
</tr>
<tr>
<td>Physical examination</td>
<td>83–4</td>
</tr>
<tr>
<td>Extratemporal epilepsy</td>
<td></td>
</tr>
<tr>
<td>Anterior frontopolar epilepsy</td>
<td>305</td>
</tr>
<tr>
<td>Cinglet gyrus epilepsy</td>
<td>304–5</td>
</tr>
<tr>
<td>Dorsolateral frontal lobe epilepsy</td>
<td>304</td>
</tr>
<tr>
<td>Frontal lobe epilepsy</td>
<td>303</td>
</tr>
<tr>
<td>Motor area epilepsy</td>
<td>305–6</td>
</tr>
<tr>
<td>Opercular epilepsy</td>
<td>304</td>
</tr>
<tr>
<td>Orbitofrontal epilepsy</td>
<td>305</td>
</tr>
<tr>
<td>Supplementary sensorimotor area seizures</td>
<td>304</td>
</tr>
<tr>
<td>Extra-temporal lobe epilepsy</td>
<td>212</td>
</tr>
<tr>
<td>Extra-temporal resection</td>
<td>212–13</td>
</tr>
</tbody>
</table>
eyelid myoclonia 22
eyelid myoclonia with absences (EMA) 260
clinical manifestations 260–1
EEG 261
epidemiology 260
genetics 260
natural history 261
treatment 262
ezogabine
  adverse effects 180
family history 80
fatty acid oxidation 228–31
febrile seizures 6, 80, 333, 344
AEDs
  therapeutic efficacy 168
definition 333–4
EEG 92–3
genetics 342–3
incidence and prevalence 334
initial evaluation 335–8
management
  in practice 341–2
  initial 335–8
  long-term 338–41
parent counselling 343–4
pathophysiology 334
prognosis 334–5
febrile seizures plus (FS+) 28–9, 259
clinical manifestations 259–60
EEG 260
epidemiology 259
genetics 259
natural history 260
treatment 260
felbamate
  adverse effects 177, 180–1
  drug interactions 154
  metabolism and excretion 149
  pharmacokinetic parameters 151
female epileptics compared with males 4–5
fluid attenuated inversion recovery (FLAIR) 108
18-fluorodeoxyglucose-positron emission tomography (FDG-PET) 115, 116
defining epileptogenic focus 206
focal cortical dysplasia (FCD)
  neuroimaging 117
focal epileptic seizures 22
EEG 96
  idiopathic 96–7
  symptomatic 98–9
fosphenytoin
  pharmacokinetic parameters 152
fractional anisotropy (FA) maps 112
free fatty acids (FFAs) 229
frontal lobe epilepsy 303
functional MRI (fMRI) 114
  defining functional or eloquent cortex 207
gabapentin
  adverse effects 177, 181
  drug interactions 154
  metabolism and excretion 149
  pharmacokinetic parameters 151
gadolinium-enhanced MR scans 109–10
ganglioglioma 125
gender differences 4–5
generalised tonic–clonic seizures (GTCS)
  20
generalized epilepsy with febrile seizures plus
  (GEFS+) 61–2
  EEG 105
  genes identified 61
generalized epileptic seizures 19
  absence seizures 21–2
  definition 19
  myoclonic seizures 20–2
generalized periodic epileptiform discharges
  (GPEs) 354–5
generalized tonic–clonic seizures 247–8
genetic epilepsy syndromes 23
genetic etiologies of epilepsy 86
genetic studies 60
  chromosomal abnormalities 63
    Angelman syndrome 64
    Miller–Dieker syndrome (MDS) 65
    Rett syndrome 64
    ring chromosome-20 65
    Wolf–Hirschhorn syndrome 63–4
  importance of 60
  pharmacogenomics 155–6
  metabolizing pathways 156–7
Gerstmann’s syndrome 213
Gestaut syndrome 292
  clinical features 293
  demographics 292
diagnostic workup 293–4
etiology 293
  treatment 293–4
  glucose transporter-1 deficiency 66
  glycine encephalopathy 66
  gradient recalled echo (GRE) imaging 109
  grand mal 20
INDEX

hamartomas of hypothalamus, 307–8
neuroimaging 119
handedness 79
hemimegalencephaly
neuroimaging 117
hemispherectomy 213
holoprosencephaly spectrum 117
hypercplexia 136
hyperventilation 91–2
ictal eye closure 308
ictal motor events
definitions 20
idiopathic epilepsy 59, 60–1
autosomal dominant lateral temporal lobe
epilepsy (ADLTE) 62–3
autosomal dominant nocturnal frontal lobe
epilepsy (ADNFLE) 62
Dravet syndrome 62
EEG 96–7, 99–102
generalized epilepsy with febrile seizures
plus (GEFS+) 61–2
juvenile myoclonic epilepsy (JME) 63
idiopathic generalised epilepsies (IGEs) 245–6,
262–3
childhood absence epilepsy (CAE) 250
clinical manifestations 251
EEG 251
epidemiology 250
genetics 250–1
natural history 251
treatment 251–2
classification 249
clinical features 246
absence seizures 247
generalized tonic–clonic seizures 247–8
myoclonic seizures 247
epilepsy with generalised tonic–clonic
seizures (IGE-GTCs) 256
clinical manifestations 257
EEG 257
epidemiology 257
genetics 257
natural history 257
treatment 257
epilepsy with myoclonic absence 257
clinical manifestations 258
EEG 258
epidemiology 258
genetics 258
natural history 258
treatment 258
epilepsy with myoclonic–atonic seizures 258
eyelid myoclonia with absences (EMA) 260
clinical manifestations 260–1
EEG 261
epidemiology 260
genetics 260
natural history 261
treatment 262
febrile seizures plus (FS+) 259
clinical manifestations 259–60
EEG 260
epidemiology 259
genetics 259
natural history 260
treatment 260
genetics 248
ILAE definition 246
Jeavons syndrome 260
clinical manifestations 260–1
EEG 261
epidemiology 260
genetics 260
natural history 261
treatment 262
juvenile absence epilepsy (JAE) 252
clinical manifestations 253
EEG 253
epidemiology 252
genetics 252
natural history 253
treatment 253
juvenile myoclonic epilepsy (JME) 253
clinical manifestations 254
EEG 254
epidemiology 254
genetics 254
natural history 255–6
epilepsy with myoclonic absence 257
clinical manifestations 258
EEG 258
epidemiology 258
genetics 258
natural history 258
treatment 258
idiopathic partial epilepsies 285–6
benign childhood epilepsy with
centrotemporal spikes (BECTs) 287–8
clinical features 288
idiopathic partial epilepsies (Continued)
- demographics 288
- diagnostic workup 289
- etiology 288–9
- treatment 289
- benign infantile seizures 286
  - clinical features 286
  - demographics 286
  - diagnostic workup 287
  - etiology 287
  - treatment 287
- childhood occipital epilepsy 289
  - clinical features 290–1
  - demographics 290
  - diagnostic workup 291–2
  - etiology 291
  - treatment 292
- late-onset childhood occipital epilepsy 292
  - clinical features 293
  - demographics 292
  - diagnostic workup 293–4
  - etiology 293
  - treatment 293–4
- idiopathic seizure etiology 40
- incidence of epilepsy 4
  - definition 4
- incontinentia pigmenti 69
- infantile spasms (IS) 270–1
  - diagnosis criteria 274
  - differential diagnosis 271
  - etiologies 272
  - prognosis 273–4
  - treatment 271–3
- infantile-onset epilepsies with encephalopathy
  - infantile spasms (IS) 270–1
    - diagnosis criteria 274
    - differential diagnosis 271
    - etiologies 272
    - prognosis 273–4
    - treatment 271–3
  - migrating focal seizures of infancy 274
  - West syndrome 270–1
- intellectual and developmental disability (IDD)
  - 12
  - prevalence with epilepsy 9
- International Classification of Epileptic Syndromes 59
- International League Against Epilepsy (ILEA) seizure classification 18–19
- intra-carotid amobarbital testing (IAT) 207–8
- intracranial monitoring 208–9

Jeavons syndrome 260
  - clinical manifestations 260–1
  - EEG 261
  - epidemiology 260
  - genetics 260
  - natural history 261
  - treatment 262
- juvenile absence epilepsy (JAE) 33, 252
  - clinical manifestations 252
  - EEG 99–102
  - EEG 253
  - epidemiology 252
  - genetics 252
  - natural history 253
  - treatment 253
- juvenile myoclonic epilepsy (JME) 33, 48, 63, 253
  - AEDs
    - therapeutic efficacy 170
    - clinical manifestations 254
    - EEG 99–102, 254
    - epidemiology 254
    - genes identified 61
    - genetics 254
    - natural history 255–6
    - treatment 256
- ketogenesis 228–31
- ketogenic diet
  - adverse effects 238
  - conditions treated 232
  - contraindications 234
  - efficacy 222–3, 224
  - comparison 226
  - initiation 235
  - maintenance 237
  - recent experience 239
  - ketone bodies 229–30
- laboratory studies 77, 85–7
- lacosamide
  - adverse effects 177, 181–2
  - drug interactions 154
  - metabolism and excretion 149
  - pharmacokinetic parameters 151
- Lafora disease 34
  - EEG 104
- lamotrigine
  - adverse effects 177, 182
  - drug interactions 154
  - initiating therapy 46
INDEX

metabolism and excretion 149
pharmacokinetic parameters 151
Landau–Kleffner syndrome (LKS) 32, 279–80
EEG 98–9
prognosis 280
treatment 280
Landau–Kleffner syndrome
AEDs
therapeutic efficacy 169
late-onset childhood occipital epilepsy (Gastaut type) 30–1
clinical features 293
demographics 292
diagnostic workup 293–4
EEG 96–7
etiology 293
treatment 293–4
late-infancy-onset epilepsies with encephalopathy
Dravet syndrome 275
course and outlook 277
differential diagnosis 275–7
etiology 275
treatment 277
severe myoclonic epilepsy of infancy (SMEI) 275
late-onset childhood occipital epilepsy 292
lateral temporal lobe epilepsy 299–300
Lennox–Gastaut syndrome (LGS) 31, 102–4, 278
AEDs
therapeutic efficacy 168
levetiracetam 8
adverse effects 177, 182
drug interactions 154
initiating therapy 46
metabolism and excretion 149
pharmacokinetic parameters 151
linear sebaceous nevus syndrome 69–70
lipolysis 228
lobotomy, temporal 211–12
low glycemic index diet 226
lumbar puncture (LP) 77

magnetic resonance imaging (MRI) 77, 78, 85
defining epileptogenic focus 205–6
imaging considerations 108–12
diffusion weighted imaging (DWI) 108–9
fluid attenuated inversion recovery (FLAIR) 108
gadolinium-enhanced MR scans 109–10
gradient recalled echo (GRE) imaging 109
susceptibility weighted imaging (SWI) 109
magnetic resonance perfusion 114
magnetic resonance spectroscopy (MRS) 114
magnetic source imaging 114–15
magnetoencephalography (MEG) 114–15, 116
defining epileptogenic focus 206
defining functional or eloquent cortex 207
male epileptics
compared with females 4–5
medial temporal lobe epilepsy 299–300
medical management
antiepileptic drug therapy
benefits 45
initiation 45–8
risks 44–5
withdrawal 51
chances of recurrent seizure after first 39
age 41
consistent factors 39–41
EEG findings 41
etiology of seizures 40
family history 41
less consistent factors 41
seizure duration 41
seizure type 41
sleep state 41
unrelated factors 41
initiating 37–9
non-surgical treatments 38
summary 48–9
long-term prognosis of childhood onset 50
seizure recurrence 42
risk following AED discontinuation 51–4
special circumstances 55–6
summary 56–7
seizure recurrence, adverse effects of 42–3
injury risks 44
learning, behavior and sleep effects 43–4
psychosocial reactions 43
special circumstances 48
withdrawing 49–50
key questions 51
pertinent scenarios 50
mesial temporal sclerosis (MTS) 126
metabolic disorders 65–6, 86
migrating focal seizures of infancy 274
Miller–Dieker syndrome (MDS) 65
minimally effective concentration (MEC) 146, 147, 153
### INDEX

- minimally toxic concentration (MTC) 146, 147, 153
- mitochondrial disorders 65–6
- motor area epilepsy 305–6
- movement disorders
  - paroxysmal dyskinesias 137–8
  - tics 137
- myoclonic absence seizures 22
- myoclonic atonic seizures 20–1
- myoclonic encephalopathy in non-progressive disorders 28
- myoclonic epilepsy in infancy (MEI) 27, 249
  - clinical manifestations 250
  - EEG 250
  - epidemiology 249
  - genetics 250
  - natural history 250
  - treatment 250
- myoclonic epilepsy with ragged-red fibers (MERRF) 34, 66
  - EEG 104
- myoclonic seizures 20–2, 247
- myoclonic–astatic epilepsy (MAE) 277–8
- negative myoclonus 20
- neonatal seizures 313, 329–30
  - adverse effects of AEDs 329
  - chronic postnatal epilepsy 328–9
  - classification and clinical features 316–17
  - electrographic seizures 317
  - etiology 321–3
  - inborn errors of metabolism 323–6
  - metabolic causes 323
  - monitoring and recording 317–21
  - pathophysiology 314–16
  - significance 313–14
  - treatment 327–8
- neonatal-onset epilepsies with encephalopathy 268–70
- neoplasms
  - neuroimaging 124–6
  - neurocutaneous disorders 67–9
  - incontinentia pigmenti 69
  - linear sebaceous nevus syndrome 69–70
  - Sturge–Weber syndrome 69
- neurodiagnostic evaluation 84
  - EEG 84–5
- neuroimaging 77, 78, 85, 107
  - acquired/idiopathic abnormalities 126–7
  - cavernomas 126–7

### mesial temporal sclerosis (MTS) 126
- post-traumatic contusions 126
- Ramussen’s encephalitis 127
- congenital malformations 117–19
- agenesis of corpus callosum (ACC) 117–18
- focal cortical dysplasia (FCD) 117
- hemimegalencephaly 117
- phakomatoses 120–4
- polymicrogyria 118–19
- schizencephaly 119
- Sturge–Weber syndrome 123–4
- tuberous sclerosis complex (TSC) 120–3

### considerations
- advanced MR 112–14
- angiography 115–16
- CT 107–8
- functional MRI (fMRI) 114
  - magnetic source imaging/magnetoencephalography 114–15
- MRI 108–12
- nuclear medicine 115
- radiography 117
- neoplasms 124–6
- neuronal ceroid lipofuscinoses (NCLs) 34
  - EEG 104
- night terrors 132
- nightmares 132
- non-convulsive status epilepticus 348
- non-epileptic seizures (NES) 134–6
- non-rapid eye movement (NREM) sleep 91, 96
- nuclear medicine 115

### occipital lobe epilepsy 306–7
- Ohtahara syndrome 25–6, 269
- onset-after-infancy epilepsies with encephalopathy
  - Doose syndrome 277–8
  - Lennox–Gastaut syndrome 278
  - myoclonic–astatic epilepsy (MAE) 277–8
  - opercular epilepsy 304
- orbitofrontal epilepsy 305
- oxcarbazepine
  - adverse effects 177, 182–4
  - drug interactions 154
  - initiating therapy 46
  - metabolism and excretion 149
  - pharmacokinetic parameters 151
Panayiotopolous syndrome 29, 289
clinical features 290–1
demographics 290
diagnostic workup 291–2
EEG 96–7
etiology 291
treatment 292
paroxysmal non-kinesigenic dyskinesias (PNKD) 137–8
parasomnias 131–2
benign sleep myoclonus of infancy 133
night terrors 132
nightmares 132
periodic limb movement disorder (PLMD) 132–3
restless leg syndrome (RLS) 132–3
sleep-related rhythmic movement disorders 133
parietal lobe epilepsy 307
paroxysmal dyskinesias 137–8
paroxysmal kinesigenic dyskinesias (PKD) 137–8
paroxysmal non-epileptic events (PNEs) 129–30, 138
alternating hemiplagia of childhood (AHC) 136–7
benign paroxysmal positional vertigo of childhood (BPVC) 133–4
breath-holding spells (BHS) 130–1
hyperekplexia 136
movement disorders
paroxysmal dyskinesias 137–8
tics 137
parasomnias 131–2
benign sleep myoclonus of infancy 133
night terrors 132
nightmares 132
periodic limb movement disorder (PLMD) 132–3
restless leg syndrome (RLS) 132–3
sleep-related rhythmic movement disorders 133
psychiatric or behavioral basis 134–6
Sandifer syndrome 138
syncope 134
partial-onset seizures
AEDs
therapeutic efficacy 170–1
perinatal risk factors 79
periodic lateralizing epileptiform discharges (PLEDs) 352–3
periodic limb movement disorder (PLMD) 132–3
phakomatoses
neuroimaging 120–4
pharmacology of AEDs 145
pharmacogenomics 155–6
metabolizing pathways 156–7
pharmacokinetics
absorption 146–7
distribution 147–8
elimination 150
metabolism 148–50
pharmacokinetic parameters 150–3
therapeutic drug monitoring (TDM) 153–5
phenobarbital 8
adverse effects 177, 184
drug interactions 154
initiating therapy 47
metabolism and excretion 149
pharmacokinetic parameters 151
phenytoin
adverse effects 177, 184–5
drug interactions 154
initiating therapy 47
metabolism and excretion 149
pharmacokinetic parameters 152
physical examination 83–4
piracetam 131
polymicrogyria
neuroimaging 118–19
poor metabolizer (PM) phenotype 156
post-traumatic contusions 126
pregabalin
adverse effects 177, 185
drug interactions 154
metabolism and excretion 149
pharmacokinetic parameters 152
prevalence of epilepsy 4
definition 4
primidone
drug interactions 154
metabolism and excretion 149
pharmacokinetic parameters 152
progressive myoclonic epilepsies (PME) 33–4, 66
EEG 104
pseudostatus epilepticus 348
psychiatric comorbidities 7
AEDs
  therapeutic efficacy 171–2
  evaluation 82–3
  related to epilepsy pathophysiology 8–9
psychiatric symptoms related to medication 8
psychogenic non-epileptic status 348
pyknolepsy 33
pyridoxine 65
radiography 117
Ramussen’s encephalitis 127
rapid eye movement (REM) sleep 91
remote symptomatic seizure etiology 40
restless leg syndrome (RLS) 132–3
Rett syndrome 64
ring chromosome-20 65
Rolandic epilepsy
  genes identified 61
rufinamide
  adverse effects 177, 185–6
  drug interactions 154
  metabolism and excretion 149
  pharmacokinetic parameters 152
Sandifer syndrome 138
schizencephaly
  neuroimaging 119
seizures
  chances of recurrence after first 39
  classification 18–19
  EEG 92–3
  etiology 40
    definitions 40
  recurrence 42
    risk following AED discontinuation 51–4
    special circumstances 55–6
    summary 56–7
  recurrence, adverse effects of 42–3
    injury risks 44
    learning, behavior and sleep effects 43–4
    psychosocial reactions 43
severe myoclonic epilepsy of infancy (SMEI)
  28, 48, 62, 275
sialidosis 34
single nucleotide polymorphisms (SNPs)
  156
single-photon emission computed tomography
  (SPECT) 115, 116
  defining epileptogenic focus 206
sleep-related rhythmic movement disorders 133
status epilepticus in childhood 346
  definition 346–7
  absence status epilepticus 347
  aura continua 347–8
  complex partial status epilepticus 347
  epilepsia partialis continua 347
  non-convulsive status epilepticus 348
  pseudostatus epilepticus 348
  psychogenic non-epileptic status 348
  status gelasticus 348
  status myoclonus 348
  subtle status epilepticus 348
  diagnosis and investigations 351–2
  EEG patterns 352
    bilaterally independent periodic
      lateralizing epileptiform discharges
      (BiPLEDs) 354
    generalized periodic epileptiform
      discharges (GPEDs) 354–5
    periodic lateralizing epileptiform
      discharges (PLEDs) 352–3
    stimulus-induced rhythmic, periodic, or
      ictal discharges (SIRPIDs) 355
    triphasic waves (TWs) 355–6
  epidemiology 349
  etiology 350–1
  pathophysiology 349–50
  prognosis 359
  treatment 356–8
    management algorithm 357
    refractory status epilepticus 358–9
  status gelasticus 348
  status myoclonus 348
Stevens–Johnson syndrome (SJS) 157
stiff baby syndrome 136
stimulus-induced rhythmic, periodic, or ictal
  discharges (SIRPIDs) 355
stress and chronic disease 7–8
structural–metabolic epilepsy syndromes
  23
Sturge–Weber syndrome 69
  neuroimaging 123–4
  subependymal giant cell astrocytomas
    (SEGAs) 122
  subtle status epilepticus 348
  superconducting quantum interference device
    (SQUID) 114
supplementary sensorimotor area seizures
  304
<table>
<thead>
<tr>
<th>INDEX</th>
<th>377</th>
</tr>
</thead>
<tbody>
<tr>
<td>surgery for epilepsy 203</td>
<td>Landau–Kleffner syndrome 169</td>
</tr>
<tr>
<td>invasive evaluation 207</td>
<td>Lennox–Gastaut syndrome 168</td>
</tr>
<tr>
<td>intra-carotid amobarbital testing (IAT) 207–8</td>
<td>neonatal seizures 164–8</td>
</tr>
<tr>
<td>intracranial monitoring 208–9</td>
<td>partial-onset seizures 170–1</td>
</tr>
<tr>
<td>non-invasive evaluation 205</td>
<td>tiagabine</td>
</tr>
<tr>
<td>defining epileptogenic focus 205–6</td>
<td>adverse effects 177, 186</td>
</tr>
<tr>
<td>defining functional or eloquent cortex 206–7</td>
<td>drug interactions 154</td>
</tr>
<tr>
<td>defining seizure events 205</td>
<td>metabolism and excretion 149</td>
</tr>
<tr>
<td>patient selection and referral 203–5</td>
<td>pharmacokinetic parameters 152</td>
</tr>
<tr>
<td>resection 209–11</td>
<td>ticcs 137</td>
</tr>
<tr>
<td>corpus callostomy 213–14</td>
<td>Todd’s paresis 77</td>
</tr>
<tr>
<td>extra-temporal resection 212–13</td>
<td>tonic seizures 20</td>
</tr>
<tr>
<td>hemispherectomy 213</td>
<td>tonic–clonic seizures 20</td>
</tr>
<tr>
<td>outcomes 214</td>
<td>topiramate 8</td>
</tr>
<tr>
<td>temporal lobectomy 211–12</td>
<td>adverse effects 177, 186</td>
</tr>
<tr>
<td>temporal lobe epilepsy 302–3</td>
<td>drug interactions 154</td>
</tr>
<tr>
<td>susceptibility weighted imaging (SWI) 109</td>
<td>initiating therapy 47</td>
</tr>
<tr>
<td>symptomatic epilepsy 59, 63</td>
<td>metabolism and excretion 149</td>
</tr>
<tr>
<td>EEG 98–9, 102</td>
<td>pharmacokinetic parameters 152</td>
</tr>
<tr>
<td>symptomatic partial epilepsies 296</td>
<td>toxic epidermal necrolysis (TEN) 157</td>
</tr>
<tr>
<td>etiology 296</td>
<td>tractography 112</td>
</tr>
<tr>
<td>seizure phenomena 297</td>
<td>treatment</td>
</tr>
<tr>
<td>temporal lobotomy 211–12</td>
<td>antiepileptic drugs (AEDs) 38</td>
</tr>
<tr>
<td>therapeutic drug monitoring (TDM) 153–5</td>
<td>breath-holding spells (BHS) 131</td>
</tr>
<tr>
<td>therapeutic efficacy of AEDs 159–60, 172</td>
<td>behavioral changes 38</td>
</tr>
<tr>
<td>comorbidities in children 171–2</td>
<td>dietary modification therapy 38</td>
</tr>
<tr>
<td>efficacy-based treatment guidelines 160–4</td>
<td>hormonal therapy 38</td>
</tr>
<tr>
<td>specific pediatric epilepsy syndromes 164</td>
<td>immune-modulating therapy 38</td>
</tr>
<tr>
<td>BECTs 169</td>
<td>vitamin deficiency supplementation 38</td>
</tr>
<tr>
<td>childhood and juvenile absence epilepsy 170</td>
<td>tricarboxylic acid (TCA) cycle 228–9</td>
</tr>
<tr>
<td>Dravet syndrome 169</td>
<td>triphasic waves (TWs) 355–6</td>
</tr>
<tr>
<td>epileptic encephalopathy with continuous spike-and-wave during sleep (ESES/CSWS) 169</td>
<td>tuberous sclerosis complex (TSC) 67–9</td>
</tr>
<tr>
<td>febrile seizures 168</td>
<td>neuroimaging 120–3</td>
</tr>
<tr>
<td>infantile spasms 168</td>
<td>typical absence seizures 21</td>
</tr>
<tr>
<td>juvenile myoclonic epilepsy (JME) 170</td>
<td>Unverricht–Lundborg disease (ULD) 34, 66</td>
</tr>
<tr>
<td>EEG 104</td>
<td>vagus nerve stimulation (VNS) therapy 193–5</td>
</tr>
<tr>
<td>advantages and disadvantages 202–3</td>
<td>candidate selection 200</td>
</tr>
<tr>
<td>clinical studies 199–200</td>
<td>complications and adverse effects 201–2</td>
</tr>
<tr>
<td>efficacy 196–8</td>
<td>experimental studies 199</td>
</tr>
<tr>
<td>history 195–6</td>
<td>initiation and maintenance 201</td>
</tr>
<tr>
<td>mechanism of action 199</td>
<td>pediatric and special populations 198–9</td>
</tr>
<tr>
<td>real-world outcomes 198</td>
<td></td>
</tr>
</tbody>
</table>
valproate
adverse effects 177, 187–8
drug interactions 154
initiating therapy 47
metabolism and excretion 149
pharmacokinetic parameters 152
vigabatrin 102
adverse effects 188–9
drug interactions 154
initiating therapy 47
metabolism and excretion 149
pharmacokinetic parameters 152

West syndrome 26–7, 270–1
AEDs
therapeutic efficacy 168
Wolf–Hirschhorn syndrome 63–4

zonisamide
adverse effects 177, 189
drug interactions 154
initiating therapy 47
metabolism and excretion 149
pharmacokinetic parameters 152